Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5658MR)

This product GTTS-WQ5658MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5658MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3239MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ4923MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ13838MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ12871MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ3470MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ13267MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ9743MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ3065MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW